
    
      To assess the effect of oral AZ D0530 at various doses on neuroimaging parameters associated
      with various forms of impulsivity mediated through glutamate-dopamine interactions, as
      ascertained through functional magnetic resonance imaging. -- --NOTE-- AZD0530 dosage of 50mg
      was discontinued by manufacturer. Adjustments were made to account for the removal of the
      50mg dosage in all arms of the study.
    
  